laboratori corp america hldg
balanc lt strategi neg
surpris ow remov top pick
labcorp ad lab industri concern lower guidanc friday
highlight issu lead roughli reduct volum
expect magnitud reduct shortli compani reduc
guidanc earn disappoint surpris lh share declin
friday vs reiter overweight rate given
view sever issu baselin said given weaker
visibl lower growth trajectori remov top pick design
lower pt repres new ep forecast
hindsight weak consum trend
surpris given recent
promot activ ancestri addit share loss relat unitedhealth
network exclus alreadi
forecast earli concess
disappoint knew come soon one factor requir
addit dilig commentari around weaker hospit referr survey
discuss industri expert suggest industri pressur still favor nation
lab scale advantag time point sentiment weak still see
catalyst network access improv go take time
market digest issu stick thesi given one-year outlook
view long-term strateg merit labcorp
observ labcorp reduc dx growth forecast impli
growth wors previous expect labcorp highlight
issu driven weak volum conceiv could
pick novemb baselin labcorp volum weak
inconsist measur track show steadi trend four issu
truli describ think compani ultim work
believ go take time market digest friday updat
case studi quest keep us opportunist long-term
strateg valu come back focu
lh quarterli annual ep usd
lower usd
return equiti ttm
link barclay live interact chart
consensu number thomson reuter receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
barclay laboratori corp america hldg
laboratori corp america hldg lh
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight labcorp good track record
execut led solid organ growth
augment value-enhanc acquisit
time expect labcorp scale advantag across
diagnost drug develop gain share
substanti free cash flow use
augment growth
labcorp integr strategi covanc yield
higher sustain growth profil compani
addit lab industri consolid lead
acceler revenu ep growth upsid
case reflect upsid ep
reimburs headwind congression
action oner clinic lab
hospit begin greater penetr esoter test
volum downsid case reflect
downsid ep
barclay laboratori corp america hldg
labcorp ad lab industri concern lower guidanc friday
highlight issu lead roughli reduct volum
expect magnitud reduct shortli compani reduc
guidanc earn disappoint surpris lh share declin
friday vs reiter overweight rate given view
sever issu baselin said given weaker visibl
lower growth trajectori remov top pick design lower
pt repres new ep forecast hindsight weak consum
trend surpris given recent promot activ ancestri
addit share loss relat network exclus alreadi
forecast earli concess disappoint knew come soon one
factor requir addit dilig commentari around weaker hospit referr
survey discuss industri expert suggest industri pressur still favor
nation lab scale advantag time point sentiment weak still
see catalyst network access improv go take time
market digest issu stick thesi given one-year outlook
view long-term strateg merit labcorp
describ reiter overweight rate labcorp remov top
pick design lower price target repres ep
forecast multipl repres current discount
prior price target repres prior ep forecast
labcorp valuat comp impli multipl mm
companytickerstock price ebitdaev ebitdamarket cap ebitdacharl impli cro barclay laboratori corp america hldg
rel lab valuat price ntm ep
labcorp reduc dx growth forecast impli
growth wors previous expect labcorp lower guidanc come
day compani report earn day host investor
headquart visit burlington nc diagnost busi tradit see
signific short-term move volum though four issu could conceiv drive
intra-quart chang repres revenu reduct midpoint
compani reduc ep forecast impli pre-tax earn
reduct flow around believ pull wors
normal labcorp scale demand didnt materi
guidanc dx dx dx organ organ growth barclay laboratori corp america hldg
labcorp highlight issu driven weak volum
conceiv could pick novemb baselin
specif compani discuss lower trend lower hospit
referr volum lost volum ahead end network exclus
advers weather event compani also note issu
list order magnitud press releas softer volum
signific four ceo dave king note issu acceler novemb
drove decis issu press releas friday compani made point
decis lower guidanc driven issu quest rais relat
reserv around revenu account receiv compani seen trend
toward greater patient respons high-deduct health plan compani bad
debt rate broadli stabl elabor issu
labcorp note lower-than-expect volum
signific issu behind lower guidanc volum novemb
came already-reduc expect said labcorp maintain
continu grow well novemb trend expect
compani recent receiv two revis forecast around test
trend includ one earlier week prior guidanc updat compani
lower forecast decemb januari though expect recoup
lost novemb busi labcorp note volum may
advers impact decis conserv around promot
anecdot notic competit promot activ ancestri black friday
front page deal amazon lower price rel labcorp
suggest may take conserv approach follow
gsk invest compani juli
 hospit referr volum labcorp also cite soft referr volum hospit
health system could driven softer util volum
impact price make us believ impact competit
natur referr volum histor gener stabl labcorp yet
determin catalyst reduct ceo dave king ad volum
soft broad-bas relat certain hospit system geograph
region test categori result trend could result lower hospit
censu chang underli util though compani say earli
determin root caus given sharp declin volum labcorp
believ hospit insourc main driver lower volum typic
insourc occur month period hospit must purchas set lab
equip lengthi process labcorp note insourc histor
led gradual eros busi case
 manag contract exclus labcorp note volum declin
specif manag care plan ahead contract open notabl
labcorp note volum declin pick novemb quest
work convert busi ahead januari end exclus
discuss investor day quest activ contact physician
target captur unitedhealthcar horizon volum ahead contract
open possibl labcorp also like see benefit aetna
volum clearli modest
weather natur disast specif volum impact
snowstorm across countri well wildfir california remind
labcorp call million revenu headwind result hurrican
barclay laboratori corp america hldg
pleas see
dx later roch
labcorp volum weak inconsist measur track show
steadi trend four issu truli describ think compani
ultim work four independ tracker includ
dx volum growth largest ivd manufactur consist grow
mid-singl digit throughout shown red line chart
estim weight averag organ growth ivd manufactur
consist mid-singl digit trend seen recent addit
individu compani result also consist roch cover emmanuel
papadaki abbott cover kristin stewart continu aggreg share
back new product launch wherea growth beckman coulter part
cover julian mitchel bio-rad siemen healthin cover
demonstr modestli weaker growth trend rel consist
lab growth trend dx manufactur
pleas see
dx trend posit
 lab director survey show volum growth expect broadli
remain posit test categori survey receiv respons around
growth declin compar result survey prior
survey expect categori posit specif expect
growth improv test categori consist result remain
categori chart creat index categori assign valu
signific declin signific growth weight respons
rate respons broadli posit bent molecular genom test
categori clear stand-out
labbeckman coulter dxbio-rad dx adj roch central pocsiemen dxweight average growth barclay laboratori corp america hldg
expect growth trend compar prior survey
barclay research weight respons signific growth growth neutral declin signific declin
 hospit adjust admiss steadi anoth measur
util track adjust admiss activ for-profit hospit
adjust admiss grew averag publicli trade provid consist
trend urban hospit post growth consist trend earlier
rural hospit declin averag consist trend follow
four straight quarter declin
urban includ tenet uhss acut segment rural includ commun health lifepoint
unemploy all-tim low labor employ growth steadi
employ trend lab august line nation averag
y/i labor forc trend lab slightli higher nation averag
y/i compar nation averag
admissionsaverageurbanrur barclay laboratori corp america hldg
employ trend averag lab model counti vs nation averag
believ go take time market digest friday updat
case studi quest keep us opportunist long-term strateg
valu come back focu labcorp project modest ep growth
valuat could constrain near term believ renew focu
acceler earn growth beyond opportun re-rat
gain better understand near-term share price opportun labcorp
look quest share perform labcorp becom unitedhealth
exclus laboratori provid januari announc octob quest
becom aetna exclus laboratori provid effect juli announc march
start quest similar situat situat labcorp
face like street rough understand
volum go shift neg net basi aetna
share declin roughli outpac
would also argu labcorp overal competit posit follow payor
network chang stack much better rel quest exclus
contract went effect put nation lab disadvantag rel
region lab could offer test aetna dynam
revers
growthlab averagen averag barclay laboratori corp america hldg
performancedgx spx barclay laboratori corp america hldg
million except per share dataestestestestestestestestestfisc year end dec growth debt gross lab growth growth ex-fx organ growth increas gross cro net growth net margin net comp net net net intang loss equiti ebitda margin net net ebit margin net expens net debt pre-tax pre-tax incom tax net net average share average share ep ep increas item net incom adj net margin net increas dilut increas ebit adj ebit margin barclay laboratori corp america hldg
meehan cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
